Depression – Pipeline Review, H2 2017
- Pages: 472
- Published: September 2017
- Report Code: GMDHC9711IDB
Global Markets Direct’s, ‘Depression – Pipeline Review, H2 2017’, provides an overview of the Depression pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Depression
The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Depression
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Depression
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4D Pharma PLC
AB Science SA
Acadia Pharmaceuticals Inc
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Alkermes Plc
Allergan Plc
Alvogen Korea Co Ltd
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Angelini Group
Araim Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
Blackthorn Therapeutics Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
Celon Pharma SA
Cerecor Inc
DAE HWA Pharmaceutical Co Ltd
Delpor Inc
DURECT Corp
Eisai Co Ltd
Eli Lilly and Company
Evotec AG
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
GlaxoSmithKline Plc
GliaCure Inc
H. Lundbeck A/S
Heptares Therapeutics Ltd
Hyundai Pharmaceutical Co Ltd
Impel NeuroPharma Inc
Insys Therapeutics Inc
Intas Pharmaceuticals Ltd
Intra-Cellular Therapies Inc
Johnson & Johnson
KemPharm Inc
Kissei Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Mapreg SAS
Medlab Clinical Ltd
Meta-IQ ApS
Mitsubishi Tanabe Pharma Corp
Navya Biologicals Pvt Ltd
Neuralstem Inc
Neurocrine Biosciences Inc
NeuroNascent Inc
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
nLife Therapeutics SL
Omeros Corp
Orexigen Therapeutics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Pherin Pharmaceuticals Inc
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Saniona AB
Servier Laboratories SAS
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Company Ltd
Tetra Discovery Partners LLC
Trevena Inc
VistaGen Therapeutics Inc
Zysis Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.